why is compound semaglutide not fda approved Proposes Ban on Bulk Compounding for Semaglutide, Tirzepatide, and Liraglutide Sprout Health GLP-1 Weight Loss

Alopecia areata update: part I

Diarrhea affected 13-16% of patients with diabetes and up to 30% in obesity trials, while vomiting occurred in 5-9% of those treated with tirzepatide for diabetes and up to 24% in obesity studies

This NIH-funded study stands as a documented case of profound ethical and regulatory failure and demands immediate, independent federal review, full transparency, and corrective action to protect public health and restore trust in human subjects research

In the add-on to sulfonylurea and add-on to insulin studies, hypoglycemia was also more commonly reported in patients treated with JANUVIA compared to placebo

Most GLP-1 programs allow you to transition to another provider or platform

Fourth, predictive biomarkers capable of reliably stratifying patients for immunotherapy and targeted treatments remain suboptimal, contributing to treatment variability and overtreatment in many cases (329)